Form 8-K KALOBIOS PHARMACEUTICALS For: Nov 17
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
KaloBios Pharma (KBIO) Could Drop 50% By Early Next Week: Tim Sykes
November 24, 2015 12:46 PM ESTTim Sykes thinks KaloBios Pharma (NASDAQ: KBIO) could drop 50% by early next week, according to the New York... More
KaloBios Pharma's (KBIO) Delisting Notification Comes as No Surprise
November 24, 2015 7:23 AM ESTKaloBios Pharma (Nasdaq: KBIO) shares are down around 9 percent following news that it received a delisting notice from the Nasdaq Stock Market. The notification comes following a sharp run higher as Martin Shkreli made a major investment in the company and was subsequently appointed as its CEO.
But, the delisting notification shouldn't come as a surprise to anyone following the stock. The company filed an... More
KaloBios Pharma (KBIO) Receives NASDAQ Delisting Notice
November 23, 2015 5:46 PM ESTThe NASDAQ Stock Market notified KaloBios Pharmaceuticals, Inc. (Nasdaq: KBIO), by letter dated November 17, 2015, that the Company is not currently in compliance with Nasdaqs continued listing requirement set forth in Rule 5250(c)(1) of the Nasdaq Listing Rules (the Rules), due to its failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2015 (the 2015 Third Quarter 10-Q) with the Securities and Exchange Commission (the SEC).
Under the Rules, the Company has 60 calendar days from November 17, 2015 to submit a plan to Nasdaq to regain compliance with the Rules. The Company intends to file... More
